ArcticZymes Technologies

Less than 1K followers

AZT

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

ArcticZymes Technologies is active in biotechnology. The company specializes in research and development of drugs for the treatment of autoimmune diseases. The main focus is on the development of glucans, the production of immunostimulants, and the analysis of enzymes. The vision is to test and develop the medicine and then further use it for RNA and DNA processes. The company was previously known as Biotec Pharmacon and is headquartered in Tromsø.

Read more
Market cap
-
Turnover
-
Revenue
112.62M
EBIT %
2.5 %
P/E
-
Dividend yield-%
-
Financial calendar
7/5
2026

Interim report Q1'26

28/5
2026

General meeting '26

14/8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
I’ve been following it, maybe a little too much. 100x San-HQ production capacity at the end of the last quarter. San 2.0 launched, with sales starting at the end of Q3, enabling a broader customer base. Lab-a-porter new distributor. New MDx customer. Virus X report completed - behind...
8/13/2021, 12:10 PM
by SuperB
5
Q2 report coming next Thursday. Has anyone (@SuperB) been following the news recently, what are the expectations?
8/13/2021, 9:52 AM
by PureProfit
4
hegnarmedia.auth.zephr.com – 3 May 21 Meglerhus tror kursfesten fortsetter Pareto Securities forventer videre kursoppgang i ArcticZymes Technologies. Paretol (Paretol) this morning gave a target price of 135 for the AstraZeneca (AZT) share
5/3/2021, 8:02 AM
by SuperB
3
Osavuosiraportti https://newsweb.oslobors.no/message/530774 Highlights from Q1 2021 ArcticZymes Technologies (AZT) had Q1 sales of NOK 40.4 million growing by 119% (Q1 2020: NOK 18.5 million) Coronavirus-related sales are estimated at NOK 16.5 million in Q1 2021 (NOK 3.8 million ...
4/22/2021, 5:49 AM
by SuperB
3
Highlights from Q2 2021 · ArcticZymes Technologies (AZT) had Q2 sales of NOK 21.4 million - a reduction of 36% (Q2 2020: NOK 33.4 million) · Coronavirus-related sales are estimated at NOK 4.5 million in Q2 2021 (NOK 11.0 million in Q2 2020) · Gross profit reduced to NOK 21.6 million...
8/19/2021, 8:19 AM
by 65HT
2
MFN – 27 Jan 22 ArcticZymes Technologies: AZT: ArcticZymes Technologies Q4 2021 Res... Tromsø, Norway, 27[th] January 2022 - ArcticZymes Technologies (OSE: AZT) reported sales of NOK 40.5 million (22.1) and an EBITDA of NOK 20.8 million (6.8) for the fourth quarter of 2021. Highligh...
1/27/2022, 6:14 AM
by sillinkutoja
1
That gross margin is moderate
4/22/2021, 7:16 AM
by ghoul
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.